Rosiglitazone(CAS:122320-73-4)

Rosiglitazone, CAS 122320-73-4, is a representative API of thiazolidinedione hypoglycemic drugs and the world’s classic pharmaceutical raw material targeted at improving insulin resistance. With unique insulin-sensitizing mechanism, stable efficacy and ultra-low hypoglycemia risk, it has been included in global pharmacopoeias and widely used in generic drug production, compound hypoglycemic formulation R&D and endocrine pharmacological research, becoming an indispensable basic API for chronic metabolic disease treatment. Featuring stable physical and chemical properties, high crystal purity and strict control over related substances, residual solvents and heavy metals, Rosiglitazone fully meets USP, EP and domestic pharmacopoeia standards. It supports industrial mass production of oral tablets and sustained-release preparations with stable batch quality and strong supply adaptability.

In terms of production and clinical safety, Rosiglitazone adopts mature synthetic and advanced purification technology with high purity and ultra-low impurities, meeting mass production and export demands of global pharmaceutical enterprises. It features stable oral absorption, mild and long-lasting efficacy, excellent long-term tolerance and no obvious liver or kidney cumulative toxicity, suitable for long-term maintenance treatment of elderly chronic disease patients. Compared with novel hypoglycemic APIs, Rosiglitazone has complete clinical application data, clear mechanism and high cost performance, maintaining stable demand in primary medical markets. As a benchmark insulin-sensitizing hypoglycemic API, it makes up for the shortcomings of traditional drugs that only lower blood glucose without improving metabolism. It maintains stable market competitiveness and broad development prospects in refined treatment of type 2 diabetes, metabolic syndrome intervention and compound hypoglycemic formulation research.